Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb)

NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) announced today that the company will begin
shipment of INFLECTRA^® (infliximab-dyyb)for
injection, a biosimilar of REMICADE^®1 (infliximab) to
wholesalers in the United States (U.S.) in late November 2016.

INFLECTRA will be the first biosimilar monoclonal antibody (mAb) and
only the second biosimilar to be available in the U.S. It is approved
for the treatment of:

• adult patients and pediatric patients (ages six years and older) with
  moderate to severely active Crohn’s disease who have had an inadequate
  response to conventional therapy;
• adult patients with moderate to severely active ulcerative colitis who
  have had an inadequate response to conventional therapy; and
• moderate to severely active rheumatoid arthritis in combination with
  methotrexate; active ankylosing spondylitis; active psoriatic
  arthritis; and chronic severe plaque psoriasis.

“Biologics have revolutionized the treatment of many life-threatening
and chronic diseases. By introducing INFLECTRA to the U.S. marketplace,
Pfizer is helping customers access an additional high quality treatment
option that promises greater savings for the healthcare system,” said
Diem Nguyen, regional president North America, Pfizer Essential Health
Business. “We are proud of our global leadership in biosimilars, and
will continue our efforts to advance a sustainable, competitive
marketplace for these therapies to deliver a high quality, consistent
supply of product and long-term savings and value for patients and
physicians.”

Pfizer holds exclusive commercialization rights to Celltrion’s INFLECTRA
in the U.S., and has already successfully introduced INFLECTRA in other
markets across the globe.

INFLECTRA will be introduced at a 15% discount to the current wholesaler
acquisition cost (WAC) of REMICADE^®, its reference product.
WAC is not inclusive of discounts to payers, providers, distributors and
other purchasing organizations.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

Only your doctor can recommend a course of treatment after checking your
health condition. INFLECTRA^® (infliximab-dyyb) can cause
serious side effects such as lowering your ability to fight infections. Some
patients, especially those 65 years and older, have had serious
infections caused by viruses, fungi or bacteria that have spread
throughout the body, including tuberculosis (TB) and histoplasmosis.
Some of these infections have been fatal. Your doctor should monitor you
closely for signs and symptoms of TB during treatment with INFLECTRA^®.

Unusual cancers have been reported in children and teenage patients
taking TNF-blocker medicines. Hepatosplenic T-cell lymphoma, a rare form
of fatal lymphoma, has occurred mostly in teenage or young adult males
with Crohn’s disease or ulcerative colitis who were taking infliximab
products and azathioprine or 6-mercaptopurine. For children and
adults taking TNF blockers, including INFLECTRA^®, the chances
of getting lymphoma or other cancers may increase.

You should discuss any concerns about your health and medical care with
your doctor.

What should I tell my doctor before I take INFLECTRA^®?

You should let your doctor know if you have or ever had any of the
following:

• Tuberculosis (TB) or have been near someone who has TB. Your doctor
  will check you for TB with a skin test. If you have latent (inactive)
  TB, you will begin TB treatment before you start INFLECTRA^®.
• Lived in a region where certain fungal infections like histoplasmosis
  or coccidioidomycosis are common.
• Infections that keep coming back, diabetes, or an immune system
  problem.
• Any type of cancer or a risk factor for developing cancer, for
  example, chronic obstructive pulmonary disease (COPD) or had
  phototherapy for psoriasis.
• Heart failure or any heart condition. Many people with heart failure
  should not take INFLECTRA^®.
• Hepatitis B virus (HBV) infection or think you may be a carrier of
  HBV. Your doctor will test you for HBV.
• Nervous system disorders (like multiple sclerosis or Guillain-Barré
  syndrome).

Also tell your doctor if you:

• Use the medicines Kineret (anakinra), Orencia (abatacept), or Actemra
  (tocilizumab) or other medicines called biologics used to treat the
  same problems as INFLECTRA^®.
• Are pregnant, plan to become pregnant, are breast-feeding, or have a
  baby and were using INFLECTRA^® during your pregnancy. Tell
  your baby’s doctor about your INFLECTRA^® use. If your baby
  receives a live vaccine within 6 months after birth, your baby may
  develop infections with serious complications that can lead to death.
• Recently received or are scheduled to receive a vaccine. Adults and
  children taking INFLECTRA^® should not receive live vaccines
  or treatment with a weakened bacteria (such as BCG for bladder cancer)
  while taking INFLECTRA^®.

What should I watch for and talk to my doctor about before or while
taking INFLECTRA^®?

The following serious (sometimes fatal) side effects have been reported
in people taking INFLECTRA^®.

You should tell your doctor right away if you have any of the signs
listed below:

• Infections (like TB, blood infections, pneumonia)—fever, tiredness,
  cough, flu, or warm, red, or painful skin or any open sores. INFLECTRA^® can
  make you more likely to get an infection or make any infection that
  you have worse.
• Lymphoma or any other cancers in adults and children.
• Skin cancer—any changes in or growths on your skin.
• Heart failure—new or worsening symptoms, such as shortness of breath,
  swelling of your ankles or feet, or sudden weight gain.
• Reactivation of HBV—feeling unwell, poor appetite, tiredness, fever,
  skin rash, and/or joint pain.
• Liver injury—jaundice (yellow skin and eyes), dark brown urine,
  right-sided abdominal pain, fever, or severe tiredness.
• Blood disorders—fever that doesn’t go away, bruising, bleeding, or
  severe paleness.
• Nervous system disorders—numbness, weakness, tingling, changes in your
  vision, or seizures.
• Allergic reactions during or after the infusion—hives, difficulty
  breathing, chest pain, high or low blood pressure, swelling of face
  and hands, and fever or chills.
• Lupus-like syndrome—chest discomfort or pain that does not go away,
  shortness of breath, joint pain, rash on the cheeks or arms that gets
  worse in the sun.
• Psoriasis—new or worsening psoriasis such as red scaly patches or
  raised bumps on the skin that are filled with pus.

The more common side effects with infliximab products are respiratory
infections (that may include sinus infections and sore throat),
headache, rash, coughing, and stomach pain.

INFLECTRA^® is a prescription medication used to treat:

Crohn’s Disease

• Can reduce signs and symptoms and induce and maintain remission in
  adult patients with moderately to severely active Crohn’s disease who
  haven’t responded well to other therapies

Pediatric Crohn’s Disease

• Can reduce signs and symptoms and induce and maintain remission in
  children (ages 6-17) with moderately to severely active Crohn’s
  disease who haven’t responded well to other therapies

Ulcerative Colitis

• Can reduce signs and symptoms, induce and maintain remission, promote
  intestinal healing, and reduce or stop the need for steroids in adult
  patients with moderately to severely active ulcerative colitis who
  haven’t responded well to other therapies

Rheumatoid Arthritis

• Can reduce signs and symptoms, help stop further joint damage, and
  improve physical function in patients with moderately to severely
  active rheumatoid arthritis, in combination with methotrexate

Ankylosing Spondylitis

• Can reduce signs and symptoms in patients with active ankylosing
  spondylitis

Psoriatic Arthritis

• Can reduce signs and symptoms of active arthritis, help stop further
  joint damage, and improve physical function in patients with psoriatic
  arthritis

Plaque Psoriasis

• Approved for the treatment of adult patients with chronic severe
  (extensive and/or disabling) plaque psoriasis under the care of a
  physician who will determine if INFLECTRA^® is appropriate
  considering other available therapies

Please see full
Prescribing Information for INFLECTRA^® (infliximab-dyyb).

About Pfizer: Working together for a healthier world^®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us. For more information, please visit us at www.pfizer.com.
In addition, to learn more, follow us on Twitter at @Pfizer
and @Pfizer_News,
LinkedIn,
YouTube
and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of
October 17, 2016. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new information or
future events or developments.

This release contains forward-looking information about INFLECTRA
(infliximab-dyyb), the timing of Pfizer’s planned shipment of INFLECTRA
to wholesalers in the United States and Pfizer’s plans with respect to
biosimilars, including their potential benefits, that involves
substantial risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, risks related to
the ability to meet anticipated shipment dates; uncertainties regarding
the commercial success of INFLECTRA; the uncertainties inherent in
research and development; intellectual property and/or litigation
implications; relationship with the application sponsor; decisions by
regulatory authorities regarding labeling and other matters that could
affect the availability or commercial potential of INFLECTRA; and
competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2015, including in the sections thereof captioned « Risk Factors » and
« Forward-Looking Information and Factors That May Affect Future
Results », as well as in its subsequent reports on Form 10-Q and Form
8-K, all of which are filed with the U.S. Securities and Exchange
Commission and available at www.sec.gov
and www.pfizer.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017006422/en/